Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Hepatic Impairment

NCT01991678 is registered in ClinicalTrials.gov with Nektar Therapeutics as lead sponsor.

NCT NCT01991678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01991678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Hepatic Impairment
Lead sponsor
Nektar Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
September 30, 2017
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors in patients with hepatic impairment